drug_type
RELEVANT_DRUG
intervention_type
Biological (gene-modified autologous cellular therapy)
drug_description
Autologous CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy produced via the PrimeCAR platform (~3-day manufacturing) with a high T-naive cell fraction; administered as a single IV infusion after lymphodepletion to treat relapsed/refractory CD19+ B-cell non-Hodgkin lymphoma. Mechanism: engineered T cells expressing a CD19-binding CAR activate via CD3ζ, proliferate, release cytokines, and mediate perforin/granzyme-dependent cytotoxicity against CD19+ B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a CD19-specific chimeric antigen receptor; upon binding CD19 on B cells, the CAR signals via CD3ζ to activate and expand the T cells, leading to cytokine release and perforin/granzyme-mediated cytotoxic killing of CD19+ malignant and normal B cells.
drug_name
MC-1-50
nct_id_drug_ref
NCT06180174